Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ...
Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback